NewsMunchies

JULY 10, 2023

Artificial intelligence is a smarter, faster, and more effective pathway to drug development. With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds major potential to increase the accessibility of drugs and to treat diseases and conditions.

Treatment 58

Treatment Research and Development Pharmaceutical Microdosing 58

Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 Furthermore, 25.4%

Consumption 109

Consumption Patients Research and Development Data 109

Veriheal

SEPTEMBER 30, 2021

Cancer patients arguably stand to benefit the most from cannabis’ unique properties and benefits, such as anti-nausea, anti-inflammation, reduced pain, inhibited tumor growth, and appetite stimulation. Additionally, the increase in the availability of cannabis research has led to a decrease in stigmatization attached to cannabis.

Patients 98

Patients Research and Development Treatment Consumption 98

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. The cannabis research problem. What makes a good research study, anyway?

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JUNE 18, 2021

CanMar Recruitment is looking for a Director of Business Development and Partnerships for our client in Montreal, Quebec. As Director of Business Development and Partnerships, you are responsible for leading and accelerating business analysis, sourcing, and deal flow activities. About Our Client. About the Role. Responsibilities.

Business 104

Business Research and Development Advocacy Data 104

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Declining circulating tumor cell (CTC) count in treated patients.

Data 100

Data Research and Development Clinical Trials Therapy 100

CannaMD

NOVEMBER 4, 2020

According to a recent study published in the Journal of Headache Pain , across 2,032 patients and 21 illnesses, headache was a symptom treated with cannabis in 24.9% (505) of cases, while 88% (445) of headache patients treated probable migraines with cannabis. 30 percent of migraine patients in the U.S. Other Research Findings.

Patients 105

Patients Chronic Pain Marijuana Research and Development 105

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

The Cannigma

JANUARY 16, 2021

Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. Anonymized data also helps scientists better understand the cannabis plant and what products and chemical profiles are most effective for treating different conditions and symptoms.

Data 100

Data Research and Development Patients Strains 100

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

DECEMBER 27, 2019

A Windsor, Ontario-based company Audacia Bioscience is especially focussed on three patented technologies that deliver consumer and patient insights to the industry to close the knowledge gaps in the supply chain. Clinical trials are medical research projects involving human participants.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. However, the survey also revealed that, among the Parkinson’s disease patients , there was a noticeable knowledge gap concerning the different methods of consumption available and the individual effects of THC and CBD.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

SpeedWeed

MARCH 14, 2021

Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.

Data 52

Data Research and Development Marijuana Collective 52

Veriheal

NOVEMBER 13, 2020

Until recently, there has been little to no research available that examines the effects of cannabis in patients diagnosed with Obsessive-Compulsive Disorder (OCD). Many patients with OCD tend to perform actions without wanting to, but feeling powerless to try and stop it. What Does Research Say About Cannabis and OCD?

Research and Development 98

Research and Development Consumption Patients Strains 98

Cannabis Law Report

MAY 29, 2022

is a Canadian company that researches, develops and grows psilocybin-producing mushrooms and functional mushrooms. Businesses have been recently receiving approval from Health Canada to farm psychedelic mushrooms, make psilocybin and sell the compound to drug-makers, or to doctors to give to patients. Optimi Health Corp.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. This latest partnership further strengthens Beckley Psytech’s digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

JULY 29, 2021

Scientists and researchers do not know exactly how or why these negative results occur, but they are still working on the question. There have been various individual studies of the condition, but the Ehave study could be the largest patient study to date. Some people have different flashback experience.

Research and Development 105

Research and Development Conditions Data Patients 105

United Patients Group

JANUARY 4, 2024

As we move forward into 2024 and beyond, the sector offers diverse paths beyond direct patient care. The growth stems from rising healthcare demand, facility expansion, and the imperative for efficient administration to maintain quality patient care. Adverse drug events (ADEs) affect approximately 7 per 100 hospitalized patients.

Research and Development 52

Research and Development Patients Data Policy 52

Cannabis Law Report

JANUARY 6, 2022

Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. By Brett Mulligan.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. MYMD-1 is being developed to treat autoimmune and age-related diseases, and to slow aging thereby increasing life-span. Acumen Research and Consulting confirmed TNF-? President, Director and Chief Medical Officer of MyMD.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

SpeedWeed

MAY 18, 2021

Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. cannabis researchers. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis.

DEA 52

DEA Research and Development Data Cannabis 52

Cannabis Law Report

DECEMBER 26, 2021

“With the filing of our provisional patent application, Entheon is building an IP foundation to better facilitate safe and precise use of psychedelics to deliver improved patient outcomes.” . – December 16, 2021) – Entheon Biomedical Corp. ” In Vivo Toxicity Assays Completed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

SEPTEMBER 23, 2021

BIMA was an Open-label safety, tolerability and proof-of-concept study to investigate the role of MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD). This data will assist Awakn’s progress by enabling a better design and more efficient execution of its clinical program.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

JANUARY 31, 2022

TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Numinus Wellness Inc.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

MMJ Recs

MARCH 16, 2024

Economic Growth and Job Creation of the medical marijuana industry The medical cannabis sector serves as a catalyst for economic expansion and workforce development in regions where it’s legalized. Moreover, ensuring product quality and safety throughout the supply chain is paramount to maintain patient trust and regulatory compliance.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Veriheal

NOVEMBER 21, 2023

Scientific research supports the potential of cannabinoids in regulating blood sugar levels, weight management, and addressing diabetic neuropathy. Quemarr’s transformative approach to diabetes treatment offers patients a less intrusive alternative to conventional insulin treatments.

Research and Development 108

Research and Development Consumption Education Data 108

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

Cannabis Law Report

AUGUST 14, 2019

Let’s take a closer look at five key ways big data and technology are directly impacting the industry. Big Data Streamlines the Marijuana Regulatory Process and Helps Close the Scientific Research Gap. Big Data Improves Distribution in the Marijuana Industry. Source: [link]. Global Cannabis Applications Corp.

Data 45

Data Research and Development Marijuana Collective 45

Cannabis Law Report

DECEMBER 9, 2021

MindMed presented FDA with a working Indications for Use statement (IFU), and a development roadmap. FDA provided key feedback regarding the draft IFU and the research methods that will lay the foundation for regulatory submissions. ” About MindMed.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Data Bridge sees strong psychedelics growth.

Research and Development 105

Research and Development Data Conditions Therapy 105

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. So, why did this educational gap develop? Unfortunately, this did not occur.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89